Company / Depreciation & Amortization
Cytek Biosciences, Inc. Depreciation & Amortization History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$7.6M
FY2025
5-year range
$603.0K / $7.6M
FY2021-FY2025
Trend
+5.1%
vs FY2024
Sector context
#122 of 142
Health Care
What the data says
Cytek Biosciences, Inc.'s depreciation & amortization of $8M is lower than 86% of companies in the Health Care sector (FY2025). Depreciation & Amortization has increased for 4 consecutive years, from $603,000 in FY2021 to $8M in FY2025.
Based on SEC 10-K filings.
$8M in FY2025 with a 5-year CAGR of +65.9%.
Increased from $6M to $8M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +44.9%
- 5-Year CAGR
- +65.9%
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 142This company $7.6M Sector average $347.4M
▼
-97.8% below sector average
Key checks
Key Insights
- Cytek Biosciences, Inc.'s depreciation & amortization has grown for 4 consecutive years.
- 5-year CAGR of +65.9%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 5.1% year-over-year.
- Ranks #122 out of 142 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.6M | +5.1% |
| FY2024 | $7.2M | +19.2% |
| FY2023 | $6.0M | +142.7% |
| FY2022 | $2.5M | +313.3% |
| FY2021 | $603.0K | +0.0% |
| FY2020 | $603.0K | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026